Anti-cancer nuclear hormone receptor-targeting compounds
US12006314B2 · kind B2 · utility
2Cited by
21References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 2, 2022 |
| Grant date | Jun 11, 2024 |
| Priority date | — |
| Expiry date | May 2, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, such as a compound of Formula I: or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, to products containing the same, as well as to methods of their use and preparation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.